Pluristem Therapeutics, Inc. (PSTI): Price and Financial Metrics
GET POWR RATINGS... FREE!
PSTI Stock Price Chart Interactive Chart >
PSTI Price/Volume Stats
| Current price | $1.00 | 52-week high | $3.45 |
| Prev. close | $1.03 | 52-week low | $0.95 |
| Day low | $0.95 | Volume | 170,600 |
| Day high | $1.05 | Avg. volume | 715,259 |
| 50-day MA | $1.27 | Dividend yield | N/A |
| 200-day MA | $1.87 | Market Cap | 32.35M |
Pluristem Therapeutics, Inc. (PSTI) Company Bio
Pluristem Therapeutics Inc. operates as a bio-therapeutics company in Israel. The company focuses on the research, development, clinical trial, and manufacture of cell therapeutics products and related technologies for the treatment of various ischemic and inflammatory conditions. The company was founded in 2001 and is based in Haifa, Israel.
Latest PSTI News From Around the Web
Below are the latest news stories about PLURISTEM THERAPEUTICS INC that investors may wish to consider to help them evaluate PSTI as an investment opportunity.
10 Biotech Penny Stocks with Growth CatalystsIn this article, we discuss 10 biotech penny stocks with growth catalysts. If you want to see some more stocks in this selection, check out 5 Biotech Penny Stocks with Growth Catalysts. According to Global Market Insights, the market for biotech in 2020 was valued at $497 billion, and it is forecasted to grow to […] |
Pluristem and Tnuva to Ring Nasdaq Closing Bell in Honor of New PartnershipClosing Bell Ringing Ceremony Will Take Place on Monday, March 28 at 3:45 pm ET at Nasdaq MarketSite in Times Square, New York A live stream of the Nasdaq Closing Bell will be available at: https://livestream.com/accounts/27896496/events/10177910 HAIFA, Israel, March 28, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI) (“Pluristem”), a leading biotechnology company, and Tnuva Group (“Tnuva Group” or “Tnuva”), Israel’s largest food producer, today announced that Pl |
Pluristem''s PLX-R18 Shows Meaningful Advantage Over Other Treatments In Transplant PatientsPluristem Therapeutics Inc (NASDAQ: PSTI ) announced final results from its hematology Phase 1 study of intramuscular injections of PLX-R18 in subjects with incomplete hematopoietic recovery following hematopoietic cell transplantation (HCT). Data collated 12 months post-treatment with PLX-R18 demonstrate that PLX-R18 was well-tolerated with … Full story available on Benzinga.com |
Pluristem PLX-R18 shows promise in blood cell recovery in cell transplant patients in trialPluristem Therapeutics (PSTI) reported final results from a phase 1 trial of intramuscular injections of PLX-R18 in patients with incomplete hematopoietic recovery following… |
Pluristem Releases PLX-R18 Hematology Phase I Study Results: Data Show Increase in All Blood Lines and Reduction in Blood TransfusionsResults show the potential in the use of PLX-R18 for meaningful advantage over other existing and proposed treatments in post hematopoietic cell transplantation (HCT) patients.PLX-R18 reduced mortality from 29% to 18%1 and was well-tolerated with a favorable safety profile.PLX-R18 was granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of graft failure and incomplete hematopoietic recovery following HCT and the prevention and treatment of acute radiat |
PSTI Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | -32.89% |
| 3-year | -73.54% |
| 5-year | -93.46% |
| YTD | N/A |
| 2022 | 0.00% |
| 2021 | -79.35% |
| 2020 | 79.44% |
| 2019 | -50.13% |
| 2018 | -42.75% |
Continue Researching PSTI
Want to do more research on Pluristem Therapeutics Inc's stock and its price? Try the links below:Pluristem Therapeutics Inc (PSTI) Stock Price | Nasdaq
Pluristem Therapeutics Inc (PSTI) Stock Quote, History and News - Yahoo Finance
Pluristem Therapeutics Inc (PSTI) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...